AION Medicines | Home

Patient centric,
ultra-long-acting medicines

Tackling the Chronic Disease Epidemic

>150 million Americans

Suffering from chronic disease requiring continuous medication

>50% regularly miss doses

Leading to hundreds of billions of avoidable healthcare costs

Next-Generation Pharmacology

Delivering ultra-long-acting solutions that maximize efficacy, improve patient adherence, and transform outcomes for chronic conditions.

A

Lower peak (C-max) → better tolerability, fewer side effects

B

Higher trough (C-trough) → enhanced efficacy, continuous target engagement‍

C

Ultra-long-acting dosing → simpler treatment, improved adherence, better outcomes

Targeting the Biggest Unmet Needs

Primary

Discovery

IND-Enabling

Clinical

AM-510

Opioid Use Disorder

Indication: Opioid Use Disorder

AM-701

Type II Diabetes, Obesity

Indication: Type II Diabetes, Obesity

Discovery Program

Decades of Experience

Aion team has developed drugs which have generated over $100 billion in revenue.

OUR TEAM

Alborz Yazdi

Co-Founder and CEO

Brian Kearney, PharmD

Chief Scientific and Development Officer

Benson Edagwa

SVP, Head of Discovery

Gary Elliott

CMC

Nick Morra

CMC

Alan Wagman

CMC

Michael Crowley

CMC

ADVISORS

Tim Garnett

Former Chief Medical Officer, Lilly

Steven Grinspoon

Head of Metabolism at Harvard MGH

Edward V. Nunes, MD

Head of Addiction Psychiatry at Columbia

Frank Vocci

Former Head of Drug Abuse at FDA, Opioid Abuse NIDA

Paul J Kenny, PhD

Chair of Neuroscience & Director of Drug Discovery at Mount Sinai

John Pottage

Former CSO & CMO, ViiV / GSK